查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2018395

胰島素輸注裝置市場規模、佔有率和趨勢分析報告：按產品、應用、地區和細分市場預測（2026-2033 年）

Insulin Delivery Devices Market Size, Share & Trends Analysis Report By Product (Reusable Insulin Pens, Disposable Insulin Pens), By End Use (Hospitals & Clinics, Homecare), By Region, And Segment Forecasts, 2026 - 2033
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

胰島素輸注裝置市場概述

全球胰島素輸注裝置市場預計到 2025 年價值 193 億美元，預計到 2033 年將達到 352 億美元。

預計從 2026 年到 2033 年，該市場將以 7.8% 的複合年成長率成長。這一成長主要是由全球糖尿病患者人數的增加所驅動的，而這反過來又推動了對先進且方便用戶使用的糖尿病管理解決方案的需求。

技術進步在市場成長中發揮著至關重要的作用，推動了更有效、更微創的設備的研發，以滿足不同患者的個人需求。此外，將數位技術整合到胰島素輸注設備中預計也將促進市場成長。這包括持續血糖監測（CGM）系統的興起，該系統與胰島素輸注設備配合使用，可提供即時血糖監測和自動胰島素劑量調整。

糖尿病管理技術的進步極大地改變了胰島素的給藥方式，從傳統的注射發展到更先進、微創的技術。最初，維持血糖值穩定是胰島素給藥的一大挑戰。然而，胰島素筆的出現使自我給藥更加便捷舒適。胰島素幫浦的研發實現了胰島素的持續輸注，進一步改善了血糖控制。持續血糖監測（CGM）設備的引入是一項決定性的進步，它能夠提供即時血糖數據，這對做出合理的決策至關重要。這為人工胰臟（APS）系統奠定了基礎，該系統將CGM數據與胰島素幫浦整合，實現自動給藥，忠實模擬胰臟的自然功能。

仿生技術融合了生物和人工過程，大大推動了胰島素給藥技術的進步。這項技術是自動胰島素幫浦（APS）等設備的基礎，這些設備利用演算法、感測器和自動幫浦來精確調節血糖值，最大限度地減少人工干預。這些創新提供了便捷的個人化解決方案，顯著改善了患者的治療效果。現代胰島素幫浦整合了動態血糖監測（CGM）、預測演算法和智慧型手機連接功能，實現了設備功能的顯著提升，從而能夠進行精準且自適應的胰島素管理。這些功能不僅降低了血糖值劇烈波動帶來的風險，還能動態地回應血糖值變化，使用戶能夠更精確地控制胰島素劑量。

隨著互聯糖尿病管理解決方案的日益普及，胰島素治療的監測和給藥方式正在發生變革，其重點在於提高患者依從性和改善臨床療效。例如，MDPI於2024年12月發表的一項研究表明，對於患有第1型糖尿病的孕婦，使用整合持續血糖監測（CGM）功能的智慧型胰島素筆可以改善血糖控制，增加血糖達標時間，且不會發生嚴重低血糖。該系統能夠自動追蹤胰島素的給藥時間和劑量，並透過配套的行動應用程式即時共用數據。這項進展表明，互聯胰島素筆技術在提高用藥依從性和最佳化糖尿病管理效果方面發揮著日益重要的作用。

此外，業界正朝著穿戴式裝置發展，例如胰島素幫浦和胰島素貼片幫浦，這些裝置能夠以便捷隱密的方式持續輸注胰島素。例如，2024年1月，瑞士醫療設備公司PharmaSens向美國FDA提交了其「niia essential」胰島素貼片幫浦系統的核准申請。此次申請是PharmaSens在胰島素幫浦技術發展過程中的關鍵一步。此外，該公司於2023年11月獲得了ISO 13485認證，該認證涵蓋胰島素輸注幫浦及其配件的設計、開發、製造和分銷。 PharmaSens的產品定位以患者需求和易用性為中心。同樣在2024年1月，Embecta公司宣布已向美國食品藥物管理局（FDA）提交了其專有的胰島素一次性輸注系統的510(k)上市前申請。

能夠追蹤和共用劑量數據的智慧胰島素筆的研發是另一個大趨勢，仿生和人工胰臟系統的進步也是如此，這些系統能夠更真實地模擬健康胰臟的天然胰島素分泌。例如，2025年7月，Byram Healthcare重點介紹了糖尿病技術的進步，指出自動胰島素輸注（AID）系統，例如貼片幫浦和整合設備，已顯著改善了血糖控制。臨床研究表明，這些系統能夠降低糖化血紅蛋白（HbA1c）水平，並延長血糖達標時間。這些系統將胰島素輸注與即時血糖監測和智慧型手機連接相結合，從而增強了數據追蹤和患者管理。這項進步反映了糖尿病照護解決方案向互聯智慧化發展的更廣泛趨勢，這些解決方案旨在模擬胰臟的自然功能。

人口老化正在推動這一行業的發展。胰島素筆、胰島素幫浦和智慧胰島素設備等裝置簡化了胰島素注射流程，而老年人由於視力、身體機能和認知功能下降等老齡化相關因素，注射胰島素往往變得特別困難。這些裝置專為滿足老年人的需求而設計。易用性、精準的劑量控制以及與數位健康平台整合的監測和提醒功能，確保了患者能夠堅持治療方案，從而改善血糖控制並降低併發症風險。鑑於全球老年人糖尿病盛行率的不斷上升，這一人群的成長潛力巨大。

目錄

第1章：調查方法和範圍

第2章執行摘要

第3章：胰島素輸注裝置市場：變數、趨勢與範圍

  • 市場譜系展望
  • 市場動態
  • 胰島素輸注裝置市場分析工具

第4章：胰島素輸注裝置市場：產品具體估算與趨勢分析

  • 全球胰島素輸注裝置市場波動分析
  • 全球胰島素輸注裝置市場：產品規模及趨勢分析（2021-2033年）
  • 胰島素筆
    • 可重複使用的胰島素筆
    • 拋棄式胰島素筆
  • 胰島素幫浦
    • 管式幫浦
    • 無管胰島素泵
  • 胰島素筆針頭
    • 標準筆針
    • 安全筆針
  • 胰島素注射器
  • 其他

第5章：胰島素輸注裝置市場：依最終用途分類的估算與趨勢分析

  • 全球胰島素輸注裝置終端用戶市場波動分析
  • 全球胰島素輸注裝置市場：按最終用途分類的規模和趨勢分析（2021-2033年）
  • 醫院和診所
  • 居家照護
  • 其他

第6章：胰島素輸注裝置市場：區域估算與趨勢分析

  • 2025年及2033年區域市佔率分析
  • 區域市場概覽
  • 全球市場概述（按地區分類）
  • 市場規模、預測與趨勢分析，2021-2033年
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 挪威
    • 瑞典
    • 丹麥
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • UAE
    • 科威特

第7章 競爭情勢

  • 主要市場參與企業近期趨勢及影響分析
  • 公司和競爭對手的分類
  • 主要企業市佔率分析，2025年
  • Company Position Analysis
  • 公司分類（新興企業、創新者、領導企業）
  • 公司簡介
    • Novo Nordisk A/S
    • Sanofi
    • Eli Lilly and Company
    • Ypsomed AG
    • Medtronic
    • Insulet Corporation
    • B. Braun SE
    • Owen Mumford Ltd.
    • Tandem Diabetes Care, Inc.
    • BD（Becton, Dickinson and Company）
Product Code: GVR-1-68038-991-3

Insulin Delivery Devices Market Summary

The global insulin delivery devices market size was estimated at USD 19.3 billion in 2025 and is expected to reach USD 35.2 billion by 2033, growing at a CAGR of 7.8% from 2026 to 2033. The growth is largely attributed to the rising global prevalence of diabetes, which has heightened the demand for advanced and user-friendly solutions for diabetes management.

Technological advancements play a crucial role in the market growth, with the development of devices that are more effective, less invasive, and tailored to meet patients' individual needs. Furthermore, integrating digital technology with insulin delivery devices is expected to boost market growth. This includes the rise of Continuous Glucose Monitoring (CGM) systems that work in tandem with insulin delivery devices to provide real-time glucose monitoring and automated insulin adjustments.

Technological advancements in diabetes management have significantly transformed insulin delivery methods, evolving from traditional injections to more advanced, minimally invasive techniques. Initially, insulin administration faced challenges in maintaining consistent blood glucose levels. However, the advent of insulin pens facilitated easier self-administration, reducing discomfort. The development of insulin pumps allowed for continuous insulin infusion, enhancing glucose control. A pivotal advancement was the introduction of Continuous Glucose Monitoring (CGM) devices, providing real-time glucose data, essential for informed decision-making. This set the stage for Artificial Pancreas Systems (APS), which integrate CGM data with insulin pumps for automated delivery, closely mimicking natural pancreatic function.

Bionic technology, blending biological and artificial processes, has been instrumental in advancing insulin delivery. It underpins devices such as APS, utilizing algorithms, sensors, and automated pumps for precise blood sugar regulation, minimizing manual intervention. These innovations offer tailored, user-friendly solutions, notably improving patient outcomes. Modern insulin pumps, equipped with CGM integration, predictive algorithms, and smartphone connectivity, exemplify significant progress in device functionality, offering accurate and adaptable insulin management. These features not only mitigate risks associated with blood glucose extremes but also empower users with finer control over their insulin dosing, responding dynamically to glucose level changes.

The increasing adoption of connected diabetes management solutions is transforming the way insulin therapy is monitored and administered, with a strong focus on improving patient adherence and clinical outcomes. For instance, in December 2024, a study published by MDPI highlighted that the use of smart insulin pens integrated with continuous glucose monitoring (CGM) in pregnant women with type 1 diabetes, demonstrating improved glycemic control and increased time-in-range without severe hypoglycemia. The system enabled automatic tracking of insulin dose timing and quantity, along with real-time data sharing through a connected mobile application. This development highlights the growing role of connected insulin pen technologies in enhancing adherence and optimizing diabetes management outcomes.

Furthermore, the industry is witnessing a shift towards wearable devices, such as insulin pumps and insulin patch pumps, which offer continuous insulin infusion in a convenient and discreet manner. For instance, in January 2024, PharmaSens, a Switzerland-based company specializing in medical devices, has recently applied for FDA approval in the United States for its 'niia essential' insulin patch pump system. This application represents a pivotal step for PharmaSens in the evolution of insulin pump technologies. Furthermore, the company achieved ISO 13485 certification in November 2023, encompassing the design, development, manufacturing, and distribution of insulin infusion pumps and their accessories. PharmaSens has positioned its product as focused on patient needs and ease of use. Furthermore, in January 2024, Embecta Corp. declared that it had submitted a 510(k) premarket application to the U.S. Food and Drug Administration (FDA) for its unique disposable insulin delivery system.

The development of smart insulin pens, which can track and share dosage data, represents another significant trend, as does the progression towards bionic and artificial pancreas systems that more closely mimic the natural insulin delivery of a healthy pancreas. For instance, in July 2025, Byram Healthcare highlighted advancements in diabetes technology, noting that automated insulin delivery (AID) systems such as patch pumps and integrated devices significantly improved glycemic control, with clinical studies showing reductions in HbA1c levels and increased time-in-range. These systems combine insulin delivery with real-time glucose monitoring and smartphone connectivity, enhancing data tracking and patient management. This development reflects the broader trend toward connected, intelligent diabetes care solutions that mimic natural pancreatic function.

The rising geriatric population is fueling the industry. These devices, such as insulin pens, pumps, and smart insulin devices, cater specifically to the needs of older adults by simplifying the insulin administration process, which can be particularly challenging due to age-related factors such as reduced vision, skill, and cognitive function. The ease of use, dosing accuracy, and the ability to integrate with digital health platforms for monitoring and reminders ensure better adherence to treatment regimens, thereby improving glycemic control & reducing the risk of complications. Given the increasing prevalence of diabetes among older adults globally, the growth potential within this demographic is substantial.

Global Insulin Delivery Devices Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global insulin delivery devices market report on the basis of product, end use, and region:

  • Product Outlook (Revenue, USD Million, 2021 - 2033)
  • Insulin Pens
    • Reusable Insulin Pens
    • Disposable Insulin Pens
  • Insulin Pumps
    • Tubed Pumps
    • Reusable Device/Components
    • Consumables
    • Tubeless Insulin Pumps
    • Reusable Device/Components
    • Consumables
  • Insulin Pen Needles
    • Standard Pen Needles
    • Safety Pen Needles
  • Insulin Syringes
  • Others
  • End Use Outlook (Revenue, USD Million, 2021 - 2033)
  • Hospitals & Clinics
  • Homecare
  • Others
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • Thailand
    • South Korea
  • Latin America
    • Brazil
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Product
    • 1.2.2. End Use
    • 1.2.3. Regional scope
    • 1.2.4. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in North America
      • 1.4.5.2. Data for primary interviews in Europe
      • 1.4.5.3. Data for primary interviews in Asia Pacific
      • 1.4.5.4. Data for primary interviews in Latin America
      • 1.4.5.5. Data for Primary interviews in MEA
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Type outlook
    • 2.2.2. End use outlook
    • 2.2.3. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Insulin Delivery Devices Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Rise in the prevalence of diabetes globally
      • 3.2.1.2. Increasing geriatric population
      • 3.2.1.3. Favorable government reimbursement scenario
      • 3.2.1.4. Increasing awareness about diabetes preventive care
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. Stringent regulatory framework
      • 3.2.2.2. High cost of devices
  • 3.3. Insulin Delivery Devices Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape

Chapter 4. Insulin Delivery Devices Market: Product Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Global Insulin Delivery Devices Product Market Movement Analysis
  • 4.3. Global Insulin Delivery Devices Market Size & Trend Analysis, by Product, 2021 to 2033 (USD Million)
  • 4.4. Insulin Pens
    • 4.4.1. Insulin pens market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.4.2. Reusable Insulin Pens
      • 4.4.2.1. Reusable insulin pens market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.4.3. Disposable Insulin Pens
      • 4.4.3.1. Disposable insulin pens market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.5. Insulin Pumps
    • 4.5.1. Insulin pumps market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.5.2. Tubed Pumps
      • 4.5.2.1. Tubed pumps market estimates and forecasts 2021 to 2033 (USD Million)
      • 4.5.2.2. Reusable Device/Components
        • 4.5.2.2.1. Reusable Device/Components market estimates and forecasts 2021 to 2033 (USD Million)
      • 4.5.2.3. Consumables
        • 4.5.2.3.1. Consumables market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.5.3. Tubeless Insulin Pumps
      • 4.5.3.1. Tubeless insulin pumps market estimates and forecasts 2021 to 2033 (USD Million)
      • 4.5.3.2. Reusable Device/Components
        • 4.5.3.2.1. Reusable Device/Components market estimates and forecasts 2021 to 2033 (USD Million)
      • 4.5.3.3. Consumables
        • 4.5.3.3.1. Consumables market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.6. Insulin Pen Needles
    • 4.6.1. Insulin pen needles market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.6.2. Standard Pen Needles
      • 4.6.2.1. Standard pen needles market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.6.3. Safety Pen Needles
      • 4.6.3.1. Safety pen needles market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.7. Insulin Syringes
    • 4.7.1. Insulin syringes market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.8. Others
    • 4.8.1. Others market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 5. Insulin Delivery Devices Market: End Use Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Global Insulin Delivery Devices End Use Market Movement Analysis
  • 5.3. Global Insulin Delivery Devices Market Size & Trend Analysis, by End Use, 2021 to 2033 (USD Million)
  • 5.4. Hospitals & Clinics
    • 5.4.1. Hospitals & clinics market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.5. Homecare
    • 5.5.1. Homecare market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.6. Others
    • 5.6.1. Other market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 6. Insulin Delivery Devices Market: Regional Estimates & Trend Analysis By Product, End Use

  • 6.1. Regional Market Share Analysis, 2025 & 2033
  • 6.2. Regional Market Dashboard
  • 6.3. Global Regional Market Snapshot
  • 6.4. Market Size, & Forecasts Trend Analysis, 2021 to 2033:
  • 6.5. North America
    • 6.5.1. U.S.
      • 6.5.1.1. Key country dynamics
      • 6.5.1.2. Competitive scenario
      • 6.5.1.3. Regulatory framework
      • 6.5.1.4. Reimbursement structure
      • 6.5.1.5. U.S. market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.5.2. Canada
      • 6.5.2.1. Key country dynamics
      • 6.5.2.2. Competitive scenario
      • 6.5.2.3. Regulatory framework
      • 6.5.2.4. Reimbursement structure
      • 6.5.2.5. Canada market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.5.3. Mexico
      • 6.5.3.1. Key country dynamics
      • 6.5.3.2. Competitive scenario
      • 6.5.3.3. Regulatory framework
      • 6.5.3.4. Reimbursement structure
      • 6.5.3.5. Mexico market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.6. Europe
    • 6.6.1. UK
      • 6.6.1.1. Key country dynamics
      • 6.6.1.2. Competitive scenario
      • 6.6.1.3. Regulatory framework
      • 6.6.1.4. Reimbursement structure
      • 6.6.1.5. UK market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.6.2. Germany
      • 6.6.2.1. Key country dynamics
      • 6.6.2.2. Competitive scenario
      • 6.6.2.3. Regulatory framework
      • 6.6.2.4. Reimbursement structure
      • 6.6.2.5. Germany market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.6.3. France
      • 6.6.3.1. Key country dynamics
      • 6.6.3.2. Competitive scenario
      • 6.6.3.3. Regulatory framework
      • 6.6.3.4. Reimbursement structure
      • 6.6.3.5. France market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.6.4. Italy
      • 6.6.4.1. Key country dynamics
      • 6.6.4.2. Competitive scenario
      • 6.6.4.3. Regulatory framework
      • 6.6.4.4. Reimbursement structure
      • 6.6.4.5. Italy market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.6.5. Spain
      • 6.6.5.1. Key country dynamics
      • 6.6.5.2. Competitive scenario
      • 6.6.5.3. Regulatory framework
      • 6.6.5.4. Reimbursement structure
      • 6.6.5.5. Spain market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.6.6. Norway
      • 6.6.6.1. Key country dynamics
      • 6.6.6.2. Competitive scenario
      • 6.6.6.3. Regulatory framework
      • 6.6.6.4. Reimbursement structure
      • 6.6.6.5. Norway market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.6.7. Sweden
      • 6.6.7.1. Key country dynamics
      • 6.6.7.2. Competitive scenario
      • 6.6.7.3. Regulatory framework
      • 6.6.7.4. Reimbursement structure
      • 6.6.7.5. Sweden market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.6.8. Denmark
      • 6.6.8.1. Key country dynamics
      • 6.6.8.2. Competitive scenario
      • 6.6.8.3. Regulatory framework
      • 6.6.8.4. Reimbursement structure
      • 6.6.8.5. Denmark market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.7. Asia Pacific
    • 6.7.1. Japan
      • 6.7.1.1. Key country dynamics
      • 6.7.1.2. Competitive scenario
      • 6.7.1.3. Regulatory framework
      • 6.7.1.4. Reimbursement structure
      • 6.7.1.5. Japan market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.7.2. China
      • 6.7.2.1. Key country dynamics
      • 6.7.2.2. Competitive scenario
      • 6.7.2.3. Regulatory framework
      • 6.7.2.4. Reimbursement structure
      • 6.7.2.5. China market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.7.3. India
      • 6.7.3.1. Key country dynamics
      • 6.7.3.2. Competitive scenario
      • 6.7.3.3. Regulatory framework
      • 6.7.3.4. Reimbursement structure
      • 6.7.3.5. India market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.7.4. Australia
      • 6.7.4.1. Key country dynamics
      • 6.7.4.2. Competitive scenario
      • 6.7.4.3. Regulatory framework
      • 6.7.4.4. Reimbursement structure
      • 6.7.4.5. Australia market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.7.5. South Korea
      • 6.7.5.1. Key country dynamics
      • 6.7.5.2. Competitive scenario
      • 6.7.5.3. Regulatory framework
      • 6.7.5.4. Reimbursement structure
      • 6.7.5.5. South Korea market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.7.6. Thailand
      • 6.7.6.1. Key country dynamics
      • 6.7.6.2. Competitive scenario
      • 6.7.6.3. Regulatory framework
      • 6.7.6.4. Reimbursement structure
      • 6.7.6.5. Thailand market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.8. Latin America
    • 6.8.1. Brazil
      • 6.8.1.1. Key country dynamics
      • 6.8.1.2. Competitive scenario
      • 6.8.1.3. Regulatory framework
      • 6.8.1.4. Reimbursement structure
      • 6.8.1.5. Brazil market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.8.2. Argentina
      • 6.8.2.1. Key country dynamics
      • 6.8.2.2. Competitive scenario
      • 6.8.2.3. Regulatory framework
      • 6.8.2.4. Reimbursement structure
      • 6.8.2.5. Argentina market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.9. MEA
    • 6.9.1. South Africa
      • 6.9.1.1. Key country dynamics
      • 6.9.1.2. Competitive scenario
      • 6.9.1.3. Regulatory framework
      • 6.9.1.4. Reimbursement structure
      • 6.9.1.5. South Africa market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.9.2. Saudi Arabia
      • 6.9.2.1. Key country dynamics
      • 6.9.2.2. Competitive scenario
      • 6.9.2.3. Regulatory framework
      • 6.9.2.4. Reimbursement structure
      • 6.9.2.5. Saudi Arabia market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.9.3. UAE
      • 6.9.3.1. Key country dynamics
      • 6.9.3.2. Competitive scenario
      • 6.9.3.3. Regulatory framework
      • 6.9.3.4. Reimbursement structure
      • 6.9.3.5. UAE market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.9.4. Kuwait
      • 6.9.4.1. Key country dynamics
      • 6.9.4.2. Competitive scenario
      • 6.9.4.3. Regulatory framework
      • 6.9.4.4. Reimbursement structure
      • 6.9.4.5. Kuwait market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 7.2. Company/Competition Categorization
  • 7.3. Key company market share analysis, 2025
  • 7.4. Company Position Analysis
  • 7.5. Company Categorization (Emerging Players, Innovators and Leaders)
  • 7.6. Company Profiles
    • 7.6.1. Novo Nordisk A/S
      • 7.6.1.1. Company overview
      • 7.6.1.2. Financial performance
      • 7.6.1.3. Product benchmarking
      • 7.6.1.4. Strategic initiatives
    • 7.6.2. Sanofi
      • 7.6.2.1. Company overview
      • 7.6.2.2. Financial performance
      • 7.6.2.3. Product benchmarking
      • 7.6.2.4. Strategic initiatives
    • 7.6.3. Eli Lilly and Company
      • 7.6.3.1. Company overview
      • 7.6.3.2. Financial performance
      • 7.6.3.4. Strategic initiatives
    • 7.6.4. Ypsomed AG
      • 7.6.4.1. Company overview
      • 7.6.4.2. Financial performance
      • 7.6.4.3. Product benchmarking
      • 7.6.4.4. Strategic initiatives
    • 7.6.5. Medtronic
      • 7.6.5.1. Company overview
      • 7.6.5.2. Financial performance
      • 7.6.5.3. Product benchmarking
      • 7.6.5.4. Strategic initiatives
    • 7.6.6. Insulet Corporation
      • 7.6.6.1. Company overview
      • 7.6.6.2. Financial performance
      • 7.6.6.3. Product benchmarking
      • 7.6.6.4. Strategic initiatives
    • 7.6.7. B. Braun SE
      • 7.6.7.1. Company overview
      • 7.6.7.2. Financial performance
      • 7.6.7.3. Product benchmarking
      • 7.6.7.4. Strategic initiatives
    • 7.6.8. Owen Mumford Ltd.
      • 7.6.8.1. Company overview
      • 7.6.8.2. Financial performance
      • 7.6.8.3. Product benchmarking
      • 7.6.8.4. Strategic initiatives
    • 7.6.9. Tandem Diabetes Care, Inc.
      • 7.6.9.1. Company overview
      • 7.6.9.2. Financial performance
      • 7.6.9.3. Product benchmarking
      • 7.6.9.4. Strategic initiatives
      • 7.6.9.5. Company overview
    • 7.6.10. BD (Becton, Dickinson and Company)
      • 7.6.10.1. Company overview
      • 7.6.10.2. Financial performance
      • 7.6.10.3. Product benchmarking
      • 7.6.10.4. Strategic initiatives
      • 7.6.10.5. Company overview

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 North America insulin delivery devices market, By country, 2021 - 2033 (USD Million)
  • Table 4 North America insulin delivery devices market, By product, 2021 - 2033 (USD Million)
  • Table 5 North America insulin delivery devices market, By end-use, 2021 - 2033 (USD Million)
  • Table 6 U.S. insulin delivery devices market, By product, 2021 - 2033 (USD Million)
  • Table 7 U.S. insulin delivery devices market, By end-use, 2021 - 2033 (USD Million)
  • Table 8 Canada insulin delivery devices market, By product, 2021 - 2033 (USD Million)
  • Table 9 Canada insulin delivery devices market, By end-use, 2021 - 2033 (USD Million)
  • Table 10 Mexico insulin delivery devices market, By product, 2021 - 2033 (USD Million)
  • Table 11 Mexico insulin delivery devices market, By end-use, 2021 - 2033 (USD Million)
  • Table 12 Europe insulin delivery devices market, By country, 2021 - 2033 (USD Million)
  • Table 13 Europe insulin delivery devices market, By product, 2021 - 2033 (USD Million)
  • Table 14 Europe insulin delivery devices market, By end-use, 2021 - 2033 (USD Million)
  • Table 15 UK insulin delivery devices market, By product, 2021 - 2033 (USD Million)
  • Table 16 UK insulin delivery devices market, By end-use, 2021 - 2033 (USD Million)
  • Table 17 Germany insulin delivery devices market, By product, 2021 - 2033 (USD Million)
  • Table 18 Germany insulin delivery devices market, By end-use, 2021 - 2033 (USD Million)
  • Table 19 France insulin delivery devices market, By product, 2021 - 2033 (USD Million)
  • Table 20 France insulin delivery devices market, By end-use, 2021 - 2033 (USD Million)
  • Table 21 Italy insulin delivery devices market, By product, 2021 - 2033 (USD Million)
  • Table 22 Italy insulin delivery devices market, By end-use, 2021 - 2033 (USD Million)
  • Table 23 Denmark insulin delivery devices market, By product, 2021 - 2033 (USD Million)
  • Table 24 Denmark insulin delivery devices market, By end-use, 2021 - 2033 (USD Million)
  • Table 25 Sweden insulin delivery devices market, By product, 2021 - 2033 (USD Million)
  • Table 26 Sweden insulin delivery devices market, By end-use, 2021 - 2033 (USD Million)
  • Table 27 Norway insulin delivery devices market, By product, 2021 - 2033 (USD Million)
  • Table 28 Norway insulin delivery devices market, By end-use, 2021 - 2033 (USD Million)
  • Table 29 Asia Pacific insulin delivery devices market, By country, 2021 - 2033 (USD Million)
  • Table 30 Asia Pacific insulin delivery devices market, By product, 2021 - 2033 (USD Million)
  • Table 31 Asia Pacific insulin delivery devices market, By end-use, 2021 - 2033 (USD Million)
  • Table 32 Japan insulin delivery devices market, By product, 2021 - 2033 (USD Million)
  • Table 33 Japan insulin delivery devices market, By end-use, 2021 - 2033 (USD Million)
  • Table 34 China insulin delivery devices market, By product, 2021 - 2033 (USD Million)
  • Table 35 China insulin delivery devices market, By end-use, 2021 - 2033 (USD Million)
  • Table 36 India insulin delivery devices market, By product, 2021 - 2033 (USD Million)
  • Table 37 India insulin delivery devices market, By end-use, 2021 - 2033 (USD Million)
  • Table 38 Australia insulin delivery devices market, By product, 2021 - 2033 (USD Million)
  • Table 39 Australia insulin delivery devices market, By end-use, 2021 - 2033 (USD Million)
  • Table 40 South Korea insulin delivery devices market, By product, 2021 - 2033 (USD Million)
  • Table 41 South Korea insulin delivery devices market, By end-use, 2021 - 2033 (USD Million)
  • Table 42 Thailand insulin delivery devices market, By product, 2021 - 2033 (USD Million)
  • Table 43 Thailand insulin delivery devices market, By end-use, 2021 - 2033 (USD Million)
  • Table 44 Latin America insulin delivery devices market, By Country, 2021 - 2033 (USD Million)
  • Table 45 Latin America insulin delivery devices market, By product, 2021 - 2033 (USD Million)
  • Table 46 Latin America insulin delivery devices market, By end-use, 2021 - 2033 (USD Million)
  • Table 47 Brazil insulin delivery devices market, By product, 2021 - 2033 (USD Million)
  • Table 48 Brazil insulin delivery devices market, By end-use, 2021 - 2033 (USD Million)
  • Table 49 Argentina insulin delivery devices market, By product, 2021 - 2033 (USD Million)
  • Table 50 Argentina insulin delivery devices market, By end-use, 2021 - 2033 (USD Million)
  • Table 51 Middle East & Africa insulin delivery devices market, By country, 2021 - 2033 (USD Million)
  • Table 52 Middle East & Africa insulin delivery devices market, By product, 2021 - 2033 (USD Million)
  • Table 53 Middle East & Africa insulin delivery devices market, By end-use, 2021 - 2033 (USD Million)
  • Table 54 South Africa insulin delivery devices market, By product, 2021 - 2033 (USD Million)
  • Table 55 South Africa insulin delivery devices market, By end-use, 2021 - 2033 (USD Million)
  • Table 56 Saudi Arabia insulin delivery devices market, By product, 2021 - 2033 (USD Million)
  • Table 57 Saudi Arabia insulin delivery devices market, By end-use, 2021 - 2033 (USD Million)
  • Table 58 UAE insulin delivery devices market, By product, 2021 - 2033 (USD Million)
  • Table 59 UAE insulin delivery devices market, By end-use, 2021 - 2033 (USD Million)
  • Table 60 Kuwait insulin delivery devices market, By product, 2021 - 2033 (USD Million)
  • Table 61 Kuwait insulin delivery devices market, By end-use, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews in North America
  • Fig. 5 Primary interviews in Europe
  • Fig. 6 Primary interviews in APAC
  • Fig. 7 Primary interviews in Latin America
  • Fig. 8 Primary interviews in the MEA
  • Fig. 9 Market research approaches
  • Fig. 10 Value-chain-based sizing & forecasting
  • Fig. 11 QFD modeling for market share assessment
  • Fig. 12 Market formulation & validation
  • Fig. 13 Insulin delivery devices market: market outlook
  • Fig. 14 Parent market outlook
  • Fig. 15 Related/ancillary market outlook
  • Fig. 16 Penetration and growth prospect mapping
  • Fig. 17 Industry value chain analysis
  • Fig. 18 Insulin delivery devices market driver impact
  • Fig. 19 Insulin delivery devices market restraint impact
  • Fig. 20 Insulin delivery devices market: Product movement analysis
  • Fig. 21 Insulin delivery devices market: Product outlook and key takeaways
  • Fig. 22 Insulin pens market estimates and forecast, 2021 - 2033
  • Fig. 23 Reusable insulin pens market estimates and forecast, 2021 - 2033
  • Fig. 24 Disposable insulin pens market estimates and forecast, 2021 - 2033
  • Fig. 25 Insulin pumps market estimates and forecast, 2021 - 2033
  • Fig. 26 Tubed Pumps market estimates and forecast, 2021 - 2033
  • Fig. 27 Reusable Device/Components market estimates and forecast, 2021 - 2033
  • Fig. 28 Consumables market estimates and forecast, 2021 - 2033
  • Fig. 29 Tubeless Insulin Pumps market estimates and forecast, 2021 - 2033
  • Fig. 30 Reusable Device/Components market estimates and forecast, 2021 - 2033
  • Fig. 31 Consumables market estimates and forecast, 2021 - 2033
  • Fig. 32 Insulin pen needles market estimates and forecast, 2021 - 2033
  • Fig. 33 Standard pen needles market estimates and forecast, 2021 - 2033
  • Fig. 34 Safety pen needles market estimates and forecast, 2021 - 2033
  • Fig. 35 Insulin syringes market estimates and forecast, 2021 - 2033
  • Fig. 36 Other market estimates and forecast, 2021 - 2033
  • Fig. 37 Insulin delivery devices market: End use movement analysis
  • Fig. 38 Insulin delivery devices market: End use outlook and key takeaways
  • Fig. 39 Hospitals and clinics market estimates and forecast, 2021 - 2033
  • Fig. 40 Homecare market estimates and forecast, 2021 - 2033
  • Fig. 41 Others end users market estimates and forecast, 2021 - 2033
  • Fig. 42 Global insulin delivery devices market: Regional movement analysis
  • Fig. 43 Global insulin delivery devices market: Regional outlook and key takeaways
  • Fig. 44 North America
  • Fig. 45 North America market estimates and forecasts, 2021 - 2033
  • Fig. 46 U.S.
  • Fig. 47 U.S. market estimates and forecasts, 2021 - 2033
  • Fig. 48 Canada
  • Fig. 49 Canada market estimates and forecasts, 2021 - 2033
  • Fig. 50 Mexico
  • Fig. 51 Mexico market estimates and forecasts, 2021 - 2033
  • Fig. 52 Europe
  • Fig. 53 Europe market estimates and forecasts, 2021 - 2033
  • Fig. 54 UK
  • Fig. 55 UK market estimates and forecasts, 2021 - 2033
  • Fig. 56 Germany
  • Fig. 57 Germany market estimates and forecasts, 2021 - 2033
  • Fig. 58 France
  • Fig. 59 France market estimates and forecasts, 2021 - 2033
  • Fig. 60 Italy
  • Fig. 61 Italy market estimates and forecasts, 2021 - 2033
  • Fig. 62 Spain
  • Fig. 63 Spain market estimates and forecasts, 2021 - 2033
  • Fig. 64 Denmark
  • Fig. 65 Denmark market estimates and forecasts, 2021 - 2033
  • Fig. 66 Sweden
  • Fig. 67 Sweden market estimates and forecasts, 2021 - 2033
  • Fig. 68 Norway
  • Fig. 69 Norway market estimates and forecasts, 2021 - 2033
  • Fig. 70 Asia Pacific
  • Fig. 71 Asia Pacific market estimates and forecasts, 2021 - 2033
  • Fig. 72 China
  • Fig. 73 China market estimates and forecasts, 2021 - 2033
  • Fig. 74 Japan
  • Fig. 75 Japan market estimates and forecasts, 2021 - 2033
  • Fig. 76 India
  • Fig. 77 India market estimates and forecasts, 2021 - 2033
  • Fig. 78 Thailand
  • Fig. 79 Thailand market estimates and forecasts, 2021 - 2033
  • Fig. 80 South Korea
  • Fig. 81 South Korea market estimates and forecasts, 2021 - 2033
  • Fig. 82 Australia
  • Fig. 83 Australia market estimates and forecasts, 2021 - 2033
  • Fig. 84 Latin America
  • Fig. 85 Latin America market estimates and forecasts, 2021 - 2033
  • Fig. 86 Brazil
  • Fig. 87 Brazil market estimates and forecasts, 2021 - 2033
  • Fig. 88 Mexico
  • Fig. 89 Mexico market estimates and forecasts, 2021 - 2033
  • Fig. 90 Argentina
  • Fig. 91 Argentina market estimates and forecasts, 2021 - 2033
  • Fig. 92 Middle East and Africa
  • Fig. 93 Middle East and Africa market estimates and forecasts, 2021 - 2033
  • Fig. 94 South Africa
  • Fig. 95 South Africa market estimates and forecasts, 2021 - 2033
  • Fig. 96 Saudi Arabia
  • Fig. 97 Saudi Arabia market estimates and forecasts, 2021 - 2033
  • Fig. 98 UAE
  • Fig. 99 UAE market estimates and forecasts, 2021 - 2033
  • Fig. 100 Kuwait
  • Fig. 101 Kuwait market estimates and forecasts, 2021 - 2033
  • Fig. 102 Market share of key market players- Insulin delivery devices market